Treatment of secondary central nervous system involvement in systemic aggressive B cell lymphoma using R-MIADD chemotherapy:a single-center study

Background:Secondary central nervous system lymphoma(SCNSL)is defined as lymphoma involvement within the central nervous system(CNS)that originated elsewhere,or a CNS relapse of systemic lymphoma.Prognosis of SCNSL is poor and the most appropriate treatment is still undetermined.Methods:We conducted a retrospective study to assess the feasibility of an R-MIADD(rituximab,high-dose methotrexate,ifosfamide,cytarabine,liposomal formulation of doxorubicin,and dexamethasone)regimen for SCNSL patients.Results:Nineteen patients with newly diagnosed CNS lesions were selected,with a median age of 58(range 20 to 72)years.Out of 19 patients,11(57.9%)achieved complete remission(CR)and 2(10.5%)achieved partial remission(PR);the overall response rate was 68.4%.The median progression-free survival after CNS involvement was 28.0 months(95%confidence interval 11.0–44.9),and the median overall survival after CNS involvement was 34.5 months.Treatment-related death occurred in one patient(5.3%).Conclusions:These single-centered data underscore the feasibility of an R-MIADD regimen as the induction therapy of SCNSL,further investigation is warranted.